OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo
OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO is OncoSec Medical’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy, which is intended to be administered using its gene delivery platform (gene electrotransfer). On […]
British pharma company Clinigen has agreed to buy the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) from Swiss pharma company Novartis in an all-cash transaction that could be worth up to $210 million. Proleukin is an FDA approved drug for metastatic melanoma and metastatic renal cell carcinoma. Clinigen has agreed to make the payments […]
Continue reading …
Business News Today
- HDFC Bank Q3 20-21 results – Indian private lender reports 18% growth in net profit at $1.2bn
- Dr. Reddy’s Laboratories gets DCGI nod for phase 3 trial of Sputnik V vaccine
- Bharti Airtel sells stake in Loan Singh creator Seynse Technologies
- Dabur India launches Dabur 100% Pure Cow Ghee
- Infosys to acquire assets of Australian design agency Carter Digital
- ICICI Bank Niyo Bharat Payroll Card launched for MSME workers
- Huntsman wraps up $250m acquisition of Gabriel Performance Products
- Janssen secures DARZALEX FASPRO FDA approval for AL amyloidosis
- Dr. Reddy’s reports success for Russian Covid-19 vaccine Sputnik V
- TCS rolls out Autoscape solution suite for autonomous and connected vehicle experiences
